Open AccessAssessment of Adipokine Expression and Mitochondrial Toxicity in HIV Patients With Lipoatrophy on Stavudine- and Zidovudine-Containing Regimens
Author(s) -
Simon P. Jones,
Nadeem A Qazi,
John Morelese,
Dirk Lebrecht,
Jussi Sutinen,
Hannele YkiJärvinen,
David Back,
Munir Pirmohamed,
Brian Gazzard,
Ulrich A. Walker,
Graeme Moyle
Publication year - 2005
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/01.qai.0000187443.30838.3e
Subject(s) - stavudine , lipodystrophy , zidovudine , adipokine , adiponectin , mitochondrial toxicity , adipose tissue , lipoatrophy , medicine , peripheral blood mononuclear cell , biology , endocrinology , immunology , leptin , viral load , toxicity , insulin , insulin resistance , virus , obesity , viral disease , biochemistry , antiretroviral therapy , in vitro
Despite evidence for the role of adipokines such as adiponectin in the metabolic toxicities of protease inhibitor (PI)-treated patients, little is known about their role in nucleoside reverse transcriptase inhibitor (NRTI)-induced lipoatrophy (LA). We analyzed the relations between mitochondrial toxicity, adipokine expression, and clinical LA in peripheral blood mononuclear cells (PBMCs) and adipose samples from individuals treated with stavudine (d4T) or zidovudine (ZDV) in comparison to patients undergoing highly active antiretroviral therapy (HAART) as well as HIV-negative individuals.